FAIM
BCRX icon

Financial Advocates Investment Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Financial Advocates Investment Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-12,708
Closed -$369K – 765
2022
Q3 		$369K Buy
+12,708
New +$164K 0.03% 495

Other funds holding BCRX

AWA
Arete Wealth Advisors Chicago, Illinois $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Financial Advocates Investment Management's BCRX Position: Q4 2022 in Review

Financial Advocates Investment Management sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2022, closing a stake of 12,708 shares — an estimated $369K sold.

Financial Advocates Investment Management first reported a position in BCRX in Q3 2022 and held it in 1 quarter. The position peaked at $369K in Q3 2022. 230 funds tracked by Wall St. Rank hold BCRX as of Q4 2022.

  • Financial Advocates Investment Management reported no remaining BioCryst Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Financial Advocates Investment Management sold 12,708 BioCryst Pharmaceuticals shares in Q4 2022, an estimated $369K.
  • Financial Advocates Investment Management first reported a position in BioCryst Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Financial Advocates Investment Management's BioCryst Pharmaceuticals position peaked at $369K in Q3 2022.
  • 230 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2022.

Based on Financial Advocates Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.